• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

意大利拉齐奥地区最大卫生机构居民中新冠病毒疫苗接种覆盖率及对严重急性呼吸综合征冠状病毒2感染的有效性:一项基于人群的队列研究

COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study.

作者信息

Fano Valeria, Coviello Enzo, Consonni Dario, Agresta Alessandro, Orsini Nicola, Crielesi Alessia, Miglietta Antonio Salvatore, Pasqua Caterina, Vairo Francesco, Vivaldi Fabio, De Angelis Giuseppe, Colaiocco Giovanni, Fabiani Massimo

机构信息

Department of Public Health, Local Health Authority Asl Roma 2, Rome, Italy.

Medical Doctor, Bari, Italy.

出版信息

Expert Rev Vaccines. 2022 Aug;21(8):1147-1157. doi: 10.1080/14760584.2022.2080057. Epub 2022 Jun 1.

DOI:10.1080/14760584.2022.2080057
PMID:35584901
Abstract

BACKGROUND

The waning of the protective effect of COVID-19 vaccines and timing of booster doses are debated.

METHODS

Population-based cohort study in the largest Health-Authority of Lazio region, Italy, on 946,156 residents aged 12+ (study period: 1 January 2021-10 January 2022). Vaccine effectiveness (VE) against any SARS-CoV-2 infection (symptomatic or asymptomatic) was estimated through multivariable negative-binomial models using unvaccinated person-time as a reference.

RESULTS

The primary vaccination cycle was completed by 81% of residents; of these, 45% received a booster dose. Vaccine coverages were lower for foreigners, and people living in deprived areas, families with children aged 0-11, and households size 1 or 6+. Overall, VE waned from 71% (95% Confidence Interval (CI) 70-73%) 1 month after the second dose to 43% (CI 41-45%) after 4 months and 24% (CI 21-27%) after 6 months, especially in the elderly aged 70+. We observed a prompt restore of VE 15-19 days after the booster dose (69%, CI 67-70%).

CONCLUSIONS

Our results support the recommendation of a booster dose 4 months after completion of the primary cycle, giving priority to elderly and fragile individuals. The lower vaccine coverage among social disadvantaged subgroups suggests the need of targeted communication and interventions.

摘要

背景

新冠疫苗保护效果的减弱以及加强针的接种时间存在争议。

方法

在意大利拉齐奥地区最大的卫生当局对946,156名12岁及以上居民进行基于人群的队列研究(研究期:2021年1月1日至2022年1月10日)。以未接种疫苗者的人时为参照,通过多变量负二项式模型估算针对任何SARS-CoV-2感染(有症状或无症状)的疫苗效力(VE)。

结果

81%的居民完成了初级疫苗接种周期;其中45%接种了加强针。外国人、生活在贫困地区的人、有0至11岁儿童的家庭以及家庭规模为1人或6人及以上者的疫苗接种率较低。总体而言,疫苗效力在第二剂接种后1个月时为71%(95%置信区间[CI] 70 - 73%),4个月后降至43%(CI 41 - 45%),6个月后降至24%(CI 21 - 27%),在70岁及以上老年人中尤其如此。我们观察到加强针接种后15至19天疫苗效力迅速恢复(69%,CI 67 - 70%)。

结论

我们的结果支持在初级周期完成后4个月接种加强针的建议,优先考虑老年人和脆弱个体。社会弱势群体亚组的疫苗接种率较低表明需要有针对性的宣传和干预措施。

相似文献

1
COVID-19 vaccines coverage and effectiveness against SARS-CoV-2 infection among residents in the largest Health Authority of Lazio region (Italy): a population-based cohort study.意大利拉齐奥地区最大卫生机构居民中新冠病毒疫苗接种覆盖率及对严重急性呼吸综合征冠状病毒2感染的有效性:一项基于人群的队列研究
Expert Rev Vaccines. 2022 Aug;21(8):1147-1157. doi: 10.1080/14760584.2022.2080057. Epub 2022 Jun 1.
2
Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in Italy, 19 July to 12 December 2021.2021 年 7 月 19 日至 12 月 12 日,在德尔塔变异株在意大利主要流行期间,mRNA 疫苗加强针在 60 岁及以上人群和其他高危人群中预防 SARS-CoV-2 感染和 COVID-19 重症的效果。
Expert Rev Vaccines. 2022 Jul;21(7):975-982. doi: 10.1080/14760584.2022.2064280. Epub 2022 Apr 15.
3
Analysis of COVID-19 Incidence and Severity Among Adults Vaccinated With 2-Dose mRNA COVID-19 or Inactivated SARS-CoV-2 Vaccines With and Without Boosters in Singapore.分析新加坡成年人接种 2 剂 mRNA COVID-19 或灭活 SARS-CoV-2 疫苗以及接种加强针后的 COVID-19 发病率和严重程度。
JAMA Netw Open. 2022 Aug 1;5(8):e2228900. doi: 10.1001/jamanetworkopen.2022.28900.
4
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2(Delta)变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络,2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.
5
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.COVID-19 疫苗效力下降和加强针的有效性和副作用:来自 ZOE COVID 研究的一项前瞻性社区研究。
Lancet Infect Dis. 2022 Jul;22(7):1002-1010. doi: 10.1016/S1473-3099(22)00146-3. Epub 2022 Apr 8.
6
COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infections, COVID-19 related hospitalizations and deaths, among individuals aged ≥65 years in Portugal: A cohort study based on data-linkage of national registries February-September 2021.COVID-19 疫苗对≥65 岁人群中出现症状的 SARS-CoV-2 感染、COVID-19 相关住院和死亡的有效性:基于国家登记数据链接的 2021 年 2 月至 9 月的队列研究。
PLoS One. 2022 Sep 13;17(9):e0274008. doi: 10.1371/journal.pone.0274008. eCollection 2022.
7
Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months.3 个月时用灭活 COVID-19 疫苗进行异源和同源加强与 6 个月时用 BNT162b2 进行同源加强的比较。
JAMA Netw Open. 2022 Aug 1;5(8):e2226046. doi: 10.1001/jamanetworkopen.2022.26046.
8
Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study.同源和异源加强针对于灭活 SARS-CoV-2 疫苗的有效性:一项大规模前瞻性队列研究。
Lancet Glob Health. 2022 Jun;10(6):e798-e806. doi: 10.1016/S2214-109X(22)00112-7. Epub 2022 Apr 23.
9
SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis.SARS-CoV-2 疫苗对感染、有症状和重症 COVID-19 的有效性:系统评价和荟萃分析。
BMC Infect Dis. 2022 May 7;22(1):439. doi: 10.1186/s12879-022-07418-y.
10
COVID-19 vaccine effectiveness among healthcare workers: a hospital-based cohort study.COVID-19 疫苗在医护人员中的有效性:一项基于医院的队列研究。
BMJ Open. 2023 May 2;13(5):e068996. doi: 10.1136/bmjopen-2022-068996.

引用本文的文献

1
Determinants of COVID-19 vaccination coverage in European and Organisation for Economic Co-operation and Development (OECD) countries.欧洲及经济合作与发展组织(经合组织)国家新冠疫苗接种覆盖率的决定因素。
Front Public Health. 2024 Dec 31;12:1466858. doi: 10.3389/fpubh.2024.1466858. eCollection 2024.
2
Determining the coverage and efficacy of the COVID-19 vaccination program at the community level in children aged 12 to 17 in Tehran.确定德黑兰12至17岁儿童社区层面新冠疫苗接种计划的覆盖率和效果。
GMS Hyg Infect Control. 2024 Jan 30;19:Doc04. doi: 10.3205/dgkh000459. eCollection 2024.
3
COVID-19 vaccination coverage for half a million non-EU migrants and refugees in England.
英格兰 50 万非欧盟移民和难民的 COVID-19 疫苗接种率。
Nat Hum Behav. 2024 Feb;8(2):288-299. doi: 10.1038/s41562-023-01768-6. Epub 2023 Dec 4.
4
Covid-19 vaccination among migrants in Rome, Italy.意大利罗马的移民中的 COVID-19 疫苗接种。
Sci Rep. 2023 Nov 28;13(1):20890. doi: 10.1038/s41598-023-48273-4.
5
COVID-19 vaccine equity: a retrospective population-based cohort study examining primary series and first booster coverage among persons with a history of immigration and other residents of Ontario, Canada.COVID-19 疫苗公平性:一项回顾性基于人群的队列研究,考察了加拿大安大略省有移民史和其他居民的初级系列和首次加强针接种情况。
Front Public Health. 2023 Sep 8;11:1232507. doi: 10.3389/fpubh.2023.1232507. eCollection 2023.